Free tool
FAERS Monitor: Qsymia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022580 or its brand name (Qsymia, Phentermine Hydrochloride, Topiramate). Reports on generic versions are filed under their own applications.
Reports
6,540
Serious
887
14% of reports
Hospitalization
222
Death reported
16
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- headache408
- paraesthesia349
- dry mouth312
- insomnia311
- dizziness297
- weight increased295
- feeling abnormal263
- inappropriate schedule of product administration257
- fatigue232
- constipation228
- nausea224
- anxiety212
- alopecia180
- product dose omission issue167
- vision blurred165
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 2 |
| 2013 | 107 |
| 2014 | 302 |
| 2015 | 398 |
| 2016 | 366 |
| 2017 | 271 |
| 2018 | 183 |
| 2019 | 162 |
| 2020 | 226 |
| 2021 | 262 |
| 2022 | 366 |
| 2023 | 794 |
| 2024 | 1,134 |
| 2025 | 1,186 |
| 2026 | 781 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,619 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dry mouthSignal | 312 | 12.4 | 11.1 | 3,262 |
| paraesthesiaSignal | 349 | 7.1 | 6.5 | 1,849 |
| inappropriate schedule of product administrationSignal | 257 | 4.6 | 4.1 | 724 |
| weight increasedSignal | 295 | 4.2 | 3.8 | 734 |
| vision blurredSignal | 165 | 3.9 | 3.3 | 350 |
| insomniaSignal | 311 | 3.8 | 3.4 | 634 |
| feeling abnormalSignal | 263 | 3.5 | 3.1 | 480 |
| constipationSignal | 228 | 3.4 | 3.0 | 380 |
| alopeciaSignal | 180 | 2.9 | 2.6 | 232 |
| anxietySignal | 212 | 2.4 | 2.1 | 173 |
| headacheSignal | 408 | 2.1 | 1.9 | 239 |
| dizziness | 297 | 1.9 | 1.7 | 132 |
| product dose omission issue | 167 | 1.8 | 1.6 | 63 |
| fatigue | 232 | 1.0 | 0.8 | 0 |
| nausea | 224 | 0.9 | 0.8 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.